Living Stronger and Longer with MPNs

Published on

Topics include: Treatments

Dr. Ruben Mesa, director of the acute and chronic leukemias program in the division of hematology-oncology at Mayo Clinic in Arizona, shares his thoughts on how treatment and research can be further improved for patients living with MPNs and the continuous exploration of combination therapy. Watch, as Dr. Mesa discusses some of the trials he’s leading that continue to help patients live stronger and longer.

View more programs featuring

Related Programs

Should Patients With a Less Advanced MPN Take a JAK2 Inhibitor?

How early should a JAK2 inhibitor be prescribed for myelofibrosis or other myeloproliferative conditions? Approved and investigational JAK2 inhibitors are now being used by patients with more advanced and aggressive MPNs, but not as often in earlier stages. Watch now as Dr. Srdan Verstovsek gives his opinion on how JAK inhibitors should be used.


MPN Research: It Takes a Village to Make a Difference

What has MPN research gained from widespread attention to this relatively rare group of diseases? Dr. Ruben Mesa, a leading researcher, explains.


Prognostic Markers that May Improve MPN Treatment

In this new video, Dr. Claire Harrison explains how testing is advancing so that we can better understand how and why MPNs manifest so differently in each patient. Watch now, as she discusses how this may affect treatment choices, outcomes, and quality of life.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on February 3, 2014